Digging into the DNDN IMPACT trial design: The trial is not powered to show the survival rate initially. The patients were in the earlier stage. The trial was changed to show the survival rate only after about half of the earlier stage patients enrolled. So the interim results might show nothing. It should be good for CEGE.